Geographic atrophy ... medical treatments are on the horizon? Researchers are working on more effective complement inhibitors and studying whether modified vitamin A could protect retinal cells.

Ocugen, Inc. (NASDAQ: OCGN) has announced the completion of dosing in the Phase 2 portion of its ArMaDa clinical trial for ...

In this CE activity, experts in the field will assess how advances in imaging and new therapies for the management of geographic atrophy ... for the treatment and management of retinal vein ...

VANCOUVER - InMed Pharmaceuticals Inc. (NASDAQ: INM), a small-cap biotech company with a market capitalization of $2.21 million, has announced the selection of an intravitreal (IVT) formulation, ...

Australia has become the first country outside of the United States to approve the use of the drug pegcetacoplan (SYFOVRE) to ...

US FDA approves expanded label for Astellas’ Izervay for the treatment of geographic atrophy: Tokyo Friday, February 14, 2025, 09:00 Hrs [IST] Astellas Pharma Inc., a global lif ...

Back to Healio Macular telangiectasia type 2 is a progressive ... the blood-retinal barrier and surround and provide nutrients to retinal neurons, become dysfunctional, leading to atrophy and ...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the U.S. Food and Drug Administration (FDA) approved expanded U.S. Prescribing information for IZERVAY™ ...

This marks the first approved treatment for ... It is a progressive and irreversible disease caused by the growth of lesions, which destroy the retinal cells responsible for vision.

Astellas Pharma seeks Japanese conditional approval of avacincaptad pegol intravitreal solution to treat geographic atrophy: Tokyo Thursday, February 6, 2025, 09:00 Hrs [IST] Aste ...

PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, today announces the first close of its ...